These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38092415)

  • 21. Biochemical Diagnosis of Acute Hepatic Porphyria: Updated Expert Recommendations for Primary Care Physicians.
    Anderson KE; Lobo R; Salazar D; Schloetter M; Spitzer G; White AL; Young RM; Bonkovsky HL; Frank EL; Mora J; Tortorelli S
    Am J Med Sci; 2021 Aug; 362(2):113-121. PubMed ID: 33865828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An Overview of Acute Hepatic Porphyrias: Clinical Implications, Diagnostic Approaches, and Management Strategies.
    Zübarioğlu T; Kıykım E; Aktuğlu-Zeybek Ç
    Turk Arch Pediatr; 2023 Jan; 58(1):3-9. PubMed ID: 36598205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute hepatic porphyrias-A guide for hepatologists.
    Moghe A; McGuire BM; Levy C
    Hepatology; 2024 Apr; ():. PubMed ID: 38607698
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice.
    Yasuda M; Gan L; Chen B; Kadirvel S; Yu C; Phillips JD; New MI; Liebow A; Fitzgerald K; Querbes W; Desnick RJ
    Proc Natl Acad Sci U S A; 2014 May; 111(21):7777-82. PubMed ID: 24821812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Porphyrias-what is verified?].
    Stölzel U; Kubisch I; Stauch T
    Internist (Berl); 2018 Dec; 59(12):1239-1248. PubMed ID: 30328490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spotlight on Givosiran as a Treatment Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy.
    Majeed CN; Ma CD; Xiao T; Rudnick S; Bonkovsky HL
    Drug Des Devel Ther; 2022; 16():1827-1845. PubMed ID: 35734365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 5-Aminolevulinate dehydratase porphyria: Update on hepatic 5-aminolevulinic acid synthase induction and long-term response to hemin.
    Lahiji AP; Anderson KE; Chan A; Simon A; Desnick RJ; Ramanujam VMS
    Mol Genet Metab; 2020 Dec; 131(4):418-423. PubMed ID: 33199206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient Perspective on Acute Hepatic Porphyria with Sporadic Attacks: A Chronic Disease with Substantial Health-Related Quality of Life Impacts.
    Wheeden K; Lyon Howe D; Burrell S; Gill L; Chamberlayne J; Williams ER; Simon A; Ko JJ; Mora J; Wells T; Evans C; Paulich M; Meninger S; Lombardelli S
    Adv Ther; 2022 Sep; 39(9):4330-4345. PubMed ID: 35907153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute hepatic porphyrias: Current diagnosis & management.
    Anderson KE
    Mol Genet Metab; 2019 Nov; 128(3):219-227. PubMed ID: 31311713
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute Hepatic Porphyrias: Review and Recent Progress.
    Wang B; Rudnick S; Cengia B; Bonkovsky HL
    Hepatol Commun; 2019 Feb; 3(2):193-206. PubMed ID: 30766957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The acute hepatic porphyrias.
    Wang B
    Transl Gastroenterol Hepatol; 2021; 6():24. PubMed ID: 33824928
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Murine models of the human porphyrias: Contributions toward understanding disease pathogenesis and the development of new therapies.
    Yasuda M; Desnick RJ
    Mol Genet Metab; 2019 Nov; 128(3):332-341. PubMed ID: 30737139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patient and caregiver experiences of living with acute hepatic porphyria in the UK: a mixed-methods study.
    Gill L; Burrell S; Chamberlayne J; Lombardelli S; Mora J; Mason N; Schurer M; Merkel M; Meninger S; Ko JJ
    Orphanet J Rare Dis; 2021 Apr; 16(1):187. PubMed ID: 33902669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanisms of Neuronal Damage in Acute Hepatic Porphyrias.
    Ricci A; Di Pierro E; Marcacci M; Ventura P
    Diagnostics (Basel); 2021 Nov; 11(12):. PubMed ID: 34943446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Givosiran to treat acute porphyria.
    Honor A; Rudnick SR; Bonkovsky HL
    Drugs Today (Barc); 2021 Jan; 57(1):47-59. PubMed ID: 33594389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks.
    Gouya L; Ventura P; Balwani M; Bissell DM; Rees DC; Stölzel U; Phillips JD; Kauppinen R; Langendonk JG; Desnick RJ; Deybach JC; Bonkovsky HL; Parker C; Naik H; Badminton M; Stein PE; Minder E; Windyga J; Bruha R; Cappellini MD; Sardh E; Harper P; Sandberg S; Aarsand AK; Andersen J; Alegre F; Ivanova A; Talbi N; Chan A; Querbes W; Ko J; Penz C; Liu S; Lin T; Simon A; Anderson KE
    Hepatology; 2020 May; 71(5):1546-1558. PubMed ID: 31512765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnosis and treatment of the hepatic porphyrias.
    Lecha M; Herrero C; Ozalla D
    Dermatol Ther; 2003; 16(1):65-72. PubMed ID: 12919129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatocellular carcinoma in acute hepatic porphyrias: A Damocles Sword.
    Peoc'h K; Manceau H; Karim Z; Wahlin S; Gouya L; Puy H; Deybach JC
    Mol Genet Metab; 2019 Nov; 128(3):236-241. PubMed ID: 30413387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kidney Involvement in Acute Hepatic Porphyrias: Pathophysiology and Diagnostic Implications.
    Ricci A; Guida CC; Manzini P; Cuoghi C; Ventura P
    Diagnostics (Basel); 2021 Dec; 11(12):. PubMed ID: 34943561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drugs and acute porphyrias: reasons for a hazardous relationship.
    Roveri G; Nascimbeni F; Rocchi E; Ventura P
    Postgrad Med; 2014 Nov; 126(7):108-20. PubMed ID: 25387219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.